Alogliptin after acute coronary syndrome in patients with type 2 diabetes: a renal function stratified analysis of the EXAMINE trial.

ABSTRACT:

Background

The EXAMINE trial tested the efficacy and safety of alogliptin, an inhibitor of dipeptidyl peptidase 4, compared with placebo in 5380 patients with type 2 diabetes and a recent acute coronary syndrome. Because alogliptin is cleared by the kidney, patients were stratified according to screening renal function within two independently randomized strata: (1) estimated glomerular filtration rate (eGFR) ≥ 60 ml/min/1.73m² and (2) eGFR < 60 ml/min/1.73m². We aim to assess the efficacy and safety of alogliptin vs. placebo according to the renal function strata.

Methods

Cox-proportional hazard models with an interaction term by renal function strata were used. The primary endpoint was a composite of cardiovascular death, nonfatal myocardial infarctio

SUBMITTER: Ferreira JP 

PROVIDER: S-EPMC7271537 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature